TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00989651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT03600155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04418427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2E11 vg/eye of ADVM-022
Description: ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
Study: NCT03932643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-201
Description: ONC-201 Capsules, 125 mg~Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle.
Study: NCT01709643

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High fat breakfast
Description: The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HF breakfast with protein
Description: For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
Study: NCT02580110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stevia glycosides

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saccharin
Study: NCT02478294

Intervention type: PROCEDURE
Intervention: Thoracoscopic LAA Excision plus AF Ablation
Description: In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.

Intervention type: DRUG
Intervention: Warfarin or Novel Oral Anticoagulants
Description: In this group, patients receive warfarin or novel oral anticoagulants
Study: NCT02721459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL888
Description: Level 1: XL888 30 mg by mouth (PO) twice weekly (BIW). Level 2: XL888 45 mg PO BIW.~Level 3: XL888 60 mg PO BIW. Level 4: XL888 90 mg PO BIW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 720 mg by mouth twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 40 mg by mouth once daily (QD). Administered 3 weeks on, 1 week off.
Study: NCT03902223

Intervention type: DIAGNOSTIC_TEST
Intervention: Enhanced Screening Protocol for Cardiac Sarcoidosis.
Description: To utilize enhanced screening tests for cardiac sarcoidosis in an undiagnosed and potentially under-diagnosed patient population to determine the rate of missed cardiac sarcoidosis diagnosis. Following testing by the standard screening tests, this intervention includes a subsequent echocardiogram and a wearable ECG, also known as a Holter Monitor or ambulatory ECG.

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Screening for Suspected Cardiac Sarcoidosis
Description: To utilize standard of care screening tests for cardiac sarcoidosis. This includes symptom check and a standard ECG.
Study: NCT06535191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistive Soft Skills and Employment Training (ASSET)
Description: ASSET program is a manualized, theory-driven, 10-week soft skills intervention for autistic individuals, who seek employment or who wish to maintain employment by improving work-related social skills. Throughout a 10-week curriculum offered in a school-based group setting, ASSET addresses the following competencies for workplace success: Communication, Networking, Enthusiasm and Attitude, Teamwork, Problem-Solving and Critical Thinking, Professionalism, Mental Health and Stress Management, and Awareness of Self and Others.
Study: NCT04418427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Commercially available Active Comparator
Study: NCT04233099

Intervention type: PROCEDURE
Intervention: Raman analysis of saliva with data collection and analysis
Description: Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.

Intervention type: PROCEDURE
Intervention: Raman analysis of saliva with data collection and analysis
Description: Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.

Intervention type: PROCEDURE
Intervention: Raman analysis of saliva with data collection and analysis
Description: Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.

Intervention type: PROCEDURE
Intervention: Raman analysis of saliva with data collection and analysis
Description: Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.

Intervention type: PROCEDURE
Intervention: Raman analysis of saliva with data collection and analysis
Description: Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
Study: NCT01134029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
Study: NCT02073084

Intervention type: DRUG
Group type: OTHER
Intervention: K-877 Low Dose
Description: K-877 Low Dose

Intervention type: DRUG
Group type: OTHER
Intervention: K-877 Low Dose
Description: K-877 Low Dose

Intervention type: DRUG
Group type: OTHER
Intervention: K-877 Low Dose
Description: K-877 Low Dose

Intervention type: DRUG
Group type: OTHER
Intervention: K-877 Low Dose
Description: K-877 Low Dose

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Study: NCT01709643

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HF breakfast with protein
Description: For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
Study: NCT04384692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study: NCT04418427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Commercially available Active Comparator

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Commercially available Active Comparator
Study: NCT02454972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Study: NCT01637311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
Study: NCT03645083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone call
Description: Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message
Description: Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
Study: NCT01956279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
Study: NCT01584778

Intervention type: OTHER
Intervention: eosinophil cationic protein
Description: Serum eosinophil cationic protein levels

Intervention type: OTHER
Intervention: eosinophil cationic protein
Description: Serum eosinophil cationic protein levels

Intervention type: OTHER
Intervention: eosinophil cationic protein
Description: Serum eosinophil cationic protein levels
Study: NCT01795703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
Study: NCT04568369

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: See treatment arm description.
Study: NCT02073084

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: K-877 High Dose
Description: K-877 High Dose

Intervention type: DRUG
Group type: OTHER
Intervention: K-877 High Dose
Description: K-877 High Dose

Intervention type: DRUG
Group type: OTHER
Intervention: K-877 High Dose
Description: K-877 High Dose

Intervention type: DRUG
Group type: OTHER
Intervention: K-877 High Dose
Description: K-877 High Dose
Study: NCT03750201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Selective Trabeculoplasty
Description: Laser surgery by automated direct automated SLT device to lower intraocular pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Trabeculoplasty
Description: Laser surgery by standard SLT device to lower intraocular pressure
Study: NCT01212367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: 1.0 x 10e12 viral particles on Days 1 and 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: 3.0 x 10e11 viral particles on Days 1 and 4
Study: NCT03289910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT03720795

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stepped Care CBT
Description: Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions.
Study: NCT04185298

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mSIM intervention plus activity monitoring
Description: Participants will receive the full mSIM intervention and be monitored (via Fitbit)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity monitoring
Description: Participants will have activity monitored (via Fitbit)
Study: NCT03504488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAB-ROR2-ADC
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAB-ROR2-ADC
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor
Study: NCT03936959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3434172
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3434172
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3434172
Description: Administered IV
Study: NCT04183322

Intervention type: BIOLOGICAL
Intervention: 13-valent pneumococcal conjugate vaccine
Study: NCT04479813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 MG
Description: Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 MG
Description: Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
Study: NCT03330665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Meditate 3 times a week using headspace app
Study: NCT00099437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection
Study: NCT03835377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron-biofortified beans
Description: Iron-biofortified beans (Phaseolus vulgaris L MIB465)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control beans
Description: Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
Study: NCT02910622

Intervention type: OTHER
Intervention: Chimio-oncogramme
Description: Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.

Intervention type: OTHER
Intervention: Chimio-oncogramme
Description: Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
Study: NCT04061967

Intervention type: OTHER
Group type: OTHER
Intervention: Sending of screening summon.
Description: 2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured.~2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent.
Study: NCT02468024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Surgery
Description: Sublobar Lung Resection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
Study: NCT04384692

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT02288247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion
Study: NCT04384692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02288247

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral
Study: NCT04568369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: See treatment arm description.
Study: NCT03764059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek™ Bulk Fill Posterior Restorative
Description: The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek™ Z350XT Universal Restorative
Description: The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
Study: NCT02619071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor sampling
Description: Bone marrow aspirate, blood sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Constiutional DNA sampling
Description: Buccal swab or Hair follicles
Study: NCT02309918

Intervention type: DRUG
Group type: OTHER
Intervention: LDV/SOF FDC
Description: Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
Study: NCT00922792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
Study: NCT02720315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive cryotherapy
Description: Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
Study: NCT02544061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM-IL-12
Description: single 12 µg unit subcutaneous (SC) dose of NM-IL-12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single subcutaneous dose
Study: NCT04078230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extend LymphAdenectomy
Description: Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
Study: NCT00168337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
Study: NCT03309410

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous to arterial conversion (v-TAC)
Description: This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous to arterial conversion (v-TAC)
Description: This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
Study: NCT00628394

Intervention type: DRUG
Group type: OTHER
Intervention: Atomoxetine
Description: 40mg 2po qam

Intervention type: DRUG
Group type: OTHER
Intervention: Atomoxetine
Description: 40mg 2po qam

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 40mg 2po qam

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 40mg 2po qam